Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3859 Comments
1149 Likes
1
Miro
Elite Member
2 hours ago
{协议答案}
👍 27
Reply
2
Payten
Insight Reader
5 hours ago
{协议答案}
👍 144
Reply
3
Annur
Daily Reader
1 day ago
{协议答案}
👍 126
Reply
4
Rayeann
Trusted Reader
1 day ago
{协议答案}
👍 148
Reply
5
Foyster
Engaged Reader
2 days ago
{协议答案}
👍 195
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.